RxDoctor Payments Data

Mohammed Rais, MD

Interventional Cardiology · Thibodaux, LANPI 1093712028

Payments from drug & device makers

$14,667in general payments, 2019–2025

Across 431 payments — averaging $34.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Angiodynamics, Inc.$7K
  • Novartis$1K
  • Johnson & Johnson$983
  • Merck$699
  • Pfizer$586
  • Boehringer Ingelheim$428
  • plus $4K from 35 others

What the payments were for

  • Food & beverage$9,06662%
  • Education$1431%
  • Other$5,45837%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$14,667 in reported general payments places this provider in the 55th percentile of 171 interventional cardiology providers in Louisiana.

See all interventional cardiology providers in Louisiana

Medicare billing

Part B allowed, 2024
$809,608
Medicare patients
583
Services billed
9,449

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban721$665,029
EntrestoSacubitril/Valsartan415$428,182
ArcalystRilonacept15$348,742
FarxigaDapagliflozin Propanediol304$253,769
JardianceEmpagliflozin278$247,935
XareltoRivaroxaban261$221,060
BrilintaTicagrelor277$175,625
Repatha SureclickEvolocumab171$144,109
VascepaIcosapent Ethyl249$132,758
VerquvoVericiguat51$53,013
NexletolBempedoic Acid64$32,460
Praluent PenAlirocumab45$27,247
WegovySemaglutide17$22,812
Nifedipine ErNifedipine895$20,368
Omega-3 Acid Ethyl Esters202$18,340

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$586$665,029721 claims
AstraZenecaFarxiga, Brilinta$371$429,394581 claims
NovartisEntresto$1,080$428,182415 claims
Kiniksa Pharmaceuticals International, PLCArcalyst$34$348,74215 claims
Boehringer IngelheimJardiance$428$247,935278 claims
Johnson & JohnsonXarelto$983$221,060261 claims
MerckVerquvo$699$53,01351 claims
Novo NordiskWegovy, Ozempic$181$35,22630 claims
Esperion Therapeutics, Inc.Nexletol$54$32,46064 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 171 interventional cardiology providers in Louisiana.

Other interventional cardiology in Thibodaux

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →